Next Article in Journal
Understanding Intratumor Heterogeneity and Evolution in NSCLC and Potential New Therapeutic Approach
Next Article in Special Issue
Role of Minimal (Measurable) Residual Disease Assessment in Older Patients with Acute Myeloid Leukemia
Previous Article in Journal
Genomic Landscapes of EBV-Associated Nasopharyngeal Carcinoma vs. HPV-Associated Head and Neck Cancer
Previous Article in Special Issue
Evolving Treatment Strategies for Elderly Leukemia Patients with IDH Mutations
Review

Immunosenescence and Immunotherapy in Elderly Acute Myeloid Leukemia Patients: Time for a Biology-Driven Approach

1
Haematology and Stem Cell Transplant Center, AORMN Marche Nord Hospital, Via Lombroso, 61100 Pesaro, Italy
2
Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology “L. and A. Seràgnoli”, University of Bologna, Via Massarenti, 9, 40138 Bologna, Italy
3
GIMEMA Foundation, 00187 Rome, Italy
*
Authors to whom correspondence should be addressed.
Received: 14 May 2018 / Revised: 9 June 2018 / Accepted: 19 June 2018 / Published: 22 June 2018
(This article belongs to the Special Issue Treatment of Older Adults with Acute Myeloid Leukemia)
Acute myeloid leukemia (AML) is a disease, which mainly affects the elderly population. Unfortunately, the prognosis of patients aged >65 years is dismal, with 1-year overall survival approaching 10% with conventional therapies. The hypothesis of harnessing the immune system against cancer, including leukemia, has been postulated for a long time, and several clinical attempts have been made in this field. In the last years, we increased our knowledge about the interplay between AML and immune cells, but no major improvement has been translated, up to now, from bench to bedside. However, the outstanding results coming from the modern immuno-oncology trials with new drugs have granted a new interest for immunotherapy in AML. Accordingly, the elderly population represents an ideal target, given the low percentage of patients eligible for allogeneic stem cell transplant. With that in mind, in the era of immunotherapy, we consider immunosenescence as the optimal background to start investigating a biology-driven approach to AML therapy in the elderly. By taking into account the physiological age-related changes of immune response, more personalized and tailored use of the new drugs and strategies harnessing the immune system against AML, has the potential to increase their efficacy and impact on clinical outcomes. View Full-Text
Keywords: acute myeloid leukemia; tumor immunity; immunotherapy; immunosenescence; new drugs; cell therapy acute myeloid leukemia; tumor immunity; immunotherapy; immunosenescence; new drugs; cell therapy
Show Figures

Figure 1

MDPI and ACS Style

Isidori, A.; Loscocco, F.; Ciciarello, M.; Corradi, G.; Lecciso, M.; Ocadlikova, D.; Parisi, S.; Salvestrini, V.; Amadori, S.; Visani, G.; Curti, A. Immunosenescence and Immunotherapy in Elderly Acute Myeloid Leukemia Patients: Time for a Biology-Driven Approach. Cancers 2018, 10, 211. https://0-doi-org.brum.beds.ac.uk/10.3390/cancers10070211

AMA Style

Isidori A, Loscocco F, Ciciarello M, Corradi G, Lecciso M, Ocadlikova D, Parisi S, Salvestrini V, Amadori S, Visani G, Curti A. Immunosenescence and Immunotherapy in Elderly Acute Myeloid Leukemia Patients: Time for a Biology-Driven Approach. Cancers. 2018; 10(7):211. https://0-doi-org.brum.beds.ac.uk/10.3390/cancers10070211

Chicago/Turabian Style

Isidori, Alessandro, Federica Loscocco, Marilena Ciciarello, Giulia Corradi, Mariangela Lecciso, Darina Ocadlikova, Sarah Parisi, Valentina Salvestrini, Sergio Amadori, Giuseppe Visani, and Antonio Curti. 2018. "Immunosenescence and Immunotherapy in Elderly Acute Myeloid Leukemia Patients: Time for a Biology-Driven Approach" Cancers 10, no. 7: 211. https://0-doi-org.brum.beds.ac.uk/10.3390/cancers10070211

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop